Biofarm S.A. (BVB:BIO)

Biofarm Cash Flow Statement

Financials in millions RON. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	100.84	100.63	74.4	77.01	70.92	60.36
Depreciation & Amortization	19.83	18.53	17.03	16.96	15.5	13.73
Loss (Gain) From Sale of Assets	-2.48	-0.68	-0.16	-0.31	-0.05	-0.21
Asset Writedown & Restructuring Costs	-10.82	-10.82	-0.13	-2.78	-1.92	-0.39
Provision & Write-off of Bad Debts	-	-	-	-1.72	-0.06	-
Other Operating Activities	-5.64	-6.28	-2.56	-11.05	-2.82	-3.56
Change in Accounts Receivable	-0.86	-19.63	-46.37	30.8	-24.58	-3.3
Change in Inventory	-20.86	-11.23	2.22	-1.65	-29.76	3.43
Change in Other Net Operating Assets	12.53	9.99	13.17	-27.43	1.79	-0.87
Operating Cash Flow	92.53	80.52	57.59	79.83	29.02	69.18
Operating Cash Flow Growth	17.04%	39.82%	-27.86%	175.10%	-58.06%	75.10%
Capital Expenditures	-17.27	-14.67	-23.41	-29.84	-30.13	-21.45
Sale of Property, Plant & Equipment	26.07	0.68	0.17	0.32	0.05	0.4
Investment in Securities	-25	7	29	-91	-	21
Other Investing Activities	10.4	9.1	7.03	6.88	2.46	0.88
Investing Cash Flow	-5.79	2.11	12.78	-113.64	-27.62	0.83
Common Dividends Paid	-29.24	-29.23	-29.19	-28.24	-22.55	-20.69
Financing Cash Flow	-29.24	-29.23	-29.19	-28.24	-22.55	-20.69
Miscellaneous Cash Flow Adjustments	-0	-0	-	-	-	-
Net Cash Flow	57.5	53.4	41.18	-62.05	-21.15	49.32
Free Cash Flow	75.26	65.86	34.18	49.99	-1.11	47.73
Free Cash Flow Growth	19.28%	92.70%	-31.63%	-	-	297.13%
Free Cash Flow Margin	23.66%	20.62%	11.92%	17.83%	-0.40%	19.97%
Free Cash Flow Per Share	0.07	0.06	0.03	0.05	-0.00	0.04
Cash Interest Paid	-	-	-	-	-	0
Cash Income Tax Paid	12.24	12.24	11.51	9.25	14.63	13.74
Levered Free Cash Flow	58.13	20.32	18.35	36.03	-21.12	40.47
Unlevered Free Cash Flow	59.22	20.32	18.35	36.03	-21.12	40.47
Change in Working Capital	-9.19	-20.86	-30.97	1.72	-52.55	-0.75

Source: S&P Global Market Intelligence. Standard template. Financial Sources.